Andera Partners’ Portfolio Company Exciva Secures €51 Million Series B to Advance Clinical Program for Alzheimer’s-Related Agitation

Andera Partners’ Portfolio Company Exciva Secures €51 Million Series B to Advance Clinical Program for Alzheimer’s-Related Agitation

• Andera Partners, seed and Series A lead investor in 2021, reinvests in Exciva as part of a Series B round led by Gimv and EQT Life Sciences, with further participation from new and existing investors
• Funding will advance Exciva’s lead program into a Phase 2 clinical study for agitation in Alzheimer’s disease

Paris, France – January 20^th, 2026 – Andera Partners, a leading European private equity player, today announced that it participated in the €51 million ($59 million) Series B financing round of its portfolio company Exciva GmbH, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions. The financing was led by Gimv and EQT Life Sciences, with further participation from new investors Fountain Healthcare Partners, LifeArc Ventures, Carma Fund and Modi VC, as well as additional existing investor LBBW.

The proceeds will primarily fund a phase 2 study evaluating Deraphan’s therapeutic potential for treating agitation in patients with Alzheimer’s disease (AD). Deraphan is the combination of two clinically validated products, including one novel chemical entity (NCE), which have demonstrated activity in the CNS field, with the potential to offer better efficacy and risk/benefit ratio than existing therapies. The clinical trial will be conducted in Europe, the UK, the US and Canada. A phase 1 trial with Deraphan has been successfully completed and showed that the combination is safe and well-tolerated.

“We are delighted that we could attract funding from both existing and new investors. This confirms that our product is highly promising,” said François Conquet, CEO of Exciva. “If the results of the phase 2 trial are positive, it will be a significant step forward in symptomatic treatment options for patients with Alzheimer’s disease.”

Raphaël Wisniewski, Partner at Andera Partners, added: “As founding investors of Exciva, we are thrilled to see this significant fundraising led by a blue-chip set of European investors. We look forward to continuing our support as the company advances its differentiated drug candidate into a large phase 2/3 trial targeting agitation in Alzheimer’s disease, a condition with a major unmet medical need.”

Following the Series B, the board of directors will be composed of Raphaël Wisniewski (Andera Partners), Philip Scheltens (EQT Life Sciences), Andreas Jurgeit (Gimv), Aidan King (Fountain Healthcare), Vikram Sudarsan (independent Board member) and François Conquet (CEO).
 

ABOUT EXCIVA

Exciva is a biopharmaceutical company founded in 2016 by Drs. Anton Bespalov, Hans Moebius and Rao Vepachedu to address neuropsychiatric symptoms in Alzheimer’s disease dementia and other brain disorders. Exciva uses its powerful discovery potential, which has led to the combination of two CNS-active compounds to treat agitation in patients living with Alzheimer’s disease dementia. Exciva is based in Heidelberg, Germany.

www.exciva.com

ABOUT ANDERA PARTNERS

Created almost 25 years ago, Andera Partners is a major player in private company investments in Europe and North America. Its teams manage over €5.1 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion/Croissance, Andera Co-Invest), sponsorless transactions (Andera Acto) and ecological transition (Andera Infra).

Andera Partners’ mission is to work alongside companies and their managers to support them in achieving strong and sustainable growth. The quality of performance offered to our investors relies on a strong partnership between the entrepreneurs in our portfolio companies and our teams, based on shared values. Performance through collective engagement, the “Power of And”, constitutes Andera Partners’ DNA.

Based in Paris, with offices in Antwerp, Madrid, Milan and Munich, Andera Partners counts 130 professionals, of which 82 investment professionals.

For further information, please visit: www.anderapartners.com.

MEDIA CONTACTS

Exciva

Andrew Lloyd & Associates
Carol Leslie: carol@ala.associates
Juliette Schmitt: juliette@ala.associates
UK : +44 1273 952 481; US : +1 203 724 5950

Andera Partners

• Nicolas DELSERT, Andera Partners: +33 6 22 67 71 17, n.delsert@anderapartners.com
• Dr. Cora KAISER, Dr. Johanna KOBLER, MC Services: +49 89 210 228 0, andera@mc-services.eu
• Paul SEBE, Bien Commun Advisory: +33 7 81 04 94 92, p.sebe@bcadvisory.fr